All chronical situations: 5 trials - PQRST - PQRST - FATS Fukosawa (probucol) - McCaughan - Tardif
| probucol vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death and non fatal MI | no data | | Coronary death | no data | | cardiac death | no data | | MACE | no data | | Non fatal MI | no data | | All cause death | no data | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| probucol vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Amputation | no data | | Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death and non fatal MI | no data | | Coronary death | no data | | cardiac death | 0.98 [0.06 15.83] | p=1.00 | 0 | 317 | 1 | Tardif, | | MACE | no data | | Non fatal MI | no data | | Revascularization | no data | | All cause death | 0.32 [0.08 1.24] | p=1.00 | 0 | 738 | 3 | PQRST,McCaughan,Tardif, | | non cardiovascular death | 0.27 [0.02 3.28] | p=1.00 | 0 | 435 | 2 | McCaughan,Tardif, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with LDL elevation and without CHD: 1 trials - FATS Fukosawa (probucol)
| probucol vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death and non fatal MI | no data | | Coronary death | no data | | cardiac death | no data | | MACE | no data | | Non fatal MI | no data | | All cause death | no data | | non cardiovascular death | no data | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with prior MI or with CHD: 2 trials - McCaughan - Tardif
| Probucol vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death and non fatal MI | no data | | Coronary death | no data | | cardiac death | 0.98 [0.06 15.83] | p=1.00 | 0 | 317 | 1 | Tardif, | | MACE | no data | | Non fatal MI | no data | | All cause death | 0.35 [0.08 1.65] | p=1.00 | 0 | 435 | 2 | McCaughan,Tardif, | | non cardiovascular death | 0.27 [0.02 3.28] | p=1.00 | 0 | 435 | 2 | McCaughan,Tardif, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - PQRST
| probucol vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Amputation | no data | | Cardiovascular death | no data | | Revascularization | no data | | All cause death | 0.20 [0.01 4.17] | p=1.00 | 0 | 303 | 1 | PQRST, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
